Samantha L Isenberg

Dr. Samantha L Isenberg

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ECElya Courtney
Elya Courtney
SISamantha L Isenberg
Samantha L Isenberg
TLTimothy Lim
Timothy Lim
CPC. Austin Pickens
C. Austin Pickens
RLRachel Lee
Rachel Lee
Konstantinos PetritisKonstantinos Petritis
Konstantinos Petritis
Lysosomal diseases (LDs, or Lysosomal Storage Disorders) have become increasingly visible in the newborn screening community, with the addition of mucopolysaccharidosis type II (MPS-II) into the Recommended Uniform Screening Panel in August 2022 and Infantile Krabbe disease in June 2024. As more LDs are expected to be considered for screening adoption, the ability to multiplex conditions and expand proficiency testing (PT) using quality control materials is essential. This study examines the use of recombinant enzymes to produce first-tier PT materials for mucopolysaccharidosis type I, MPS-II, Gaucher, Fabry, Krabbe, Pompe, and Niemann–Pick A/B (acid sphingomyelinase deficiency)—adding four disorders to the CDC’s Newborn Screening Quality Assurance Program (NSQAP) LD PT panel. Through an iterative process that included two prototype phases, two pilot phases, and external testing by up to 31 external laboratories, a new manufacturing process was developed for producing high-performing dried blood spot-based LD PT specimens. Materials were evaluated using several methods commonly employed by newborn screening laboratories, including tandem mass spectrometry with flow injection and liquid chromatography, digital microfluidics, and fluorometric assays. This novel process for producing LD PT materials offers several advantages over previous manufacturing methods that relied on immortalized cell lines from affected patients. Improved scalability, for example, has enabled NSQAP to expand LD PT enrollment internationally. Furthermore, the new process makes it easier to support future expansions of the LD screening panel. The updated specimens and expanded program were launched in January 2025.

1 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
CPC. Austin Pickens
C. Austin Pickens
SSSamyukta Sah
Samyukta Sah
RCRahul Chandrappa
Rahul Chandrappa
SISamantha L Isenberg
Samantha L Isenberg
ECElya Courtney
Elya Courtney
Konstantinos PetritisKonstantinos Petritis
Konstantinos Petritis
Background: Parenteral nutrition (PN) is a nutrient solution administered intravenously (IV) to premature babies. PN causes elevations of some amino acids in blood samples that are also biomarkers used in newborn screening (NBS). Therefore, PN status must be annotated on dried blood spot (DBS) cards by clinicians to reduce NBS laboratory burdens associated with potential false results, however, NBS laboratories continue to receive DBS with misannotated PN status. N-acetyltyrosine (NAT), a water-soluble tyrosine analog used to increase tyrosine bioavailability in PN solutions, can be used as a blood-based biomarker of PN administration in NBS assays. Methods: Residual DBS specimens and manufactured DBS were used in analyses. The assay was developed and validated using flow injection analysis tandem mass spectrometry (FIA-MS/MS) for detection of NAT. Results: NAT was only present in neonate DBS with annotated PN administration, and was multiplexed into first-tier newborn screening assays. NAT was highly correlated with amino acids present in PN solutions such as arginine, leucine, methionine, phenylalanine, and valine. In our sample cohort, we determined an NAT cutoff could aid identification of misannotated neonates administered PN. We also report the Amadori rearrangement product valine-hexose (Val-Hex) was quantifiable in neonates administered PN, which we suspect forms in the PN solution and/or IV lines. Conclusions: Here we present the first known use of NAT as a biomarker for PN administration, which is currently being piloted by two U.S. NBS laboratories. NAT and Val-Hex can aid identification of misannotated DBS from neonates administered PN, thus, decreasing false positive rates.

Verified
Journal Article
Open access
CPC. Austin Pickens
C. Austin Pickens
SSSamyukta Sah
Samyukta Sah
RCRahul Chandrappa
Rahul Chandrappa
SISamantha L Isenberg
Samantha L Isenberg
ECElya Courtney
Elya Courtney
Konstantinos PetritisKonstantinos Petritis
Konstantinos Petritis
Parenteral nutrition (PN) is a nutrient solution administered intravenously (IV) to premature babies. PN causes elevations of some amino acids in blood samples that are also biomarkers used in newborn screening (NBS). Therefore, PN status must be annotated by clinicians on dried blood spot (DBS) cards to reduce NBS laboratory burdens associated with potential false results; however, NBS laboratories continue to receive DBSs with misannotated PN status. N-acetyltyrosine (NAT), a water-soluble tyrosine analog used to increase tyrosine bioavailability in PN solutions, can be used as a blood-based biomarker of PN administration in NBS assays. Residual DBS specimens and manufactured DBSs were used in analyses. The assay was developed and validated using flow injection analysis tandem mass spectrometry (FIA-MS/MS) for the detection of NAT. NAT was only present in neonate DBSs with annotated PN administration and was multiplexed into first-tier newborn screening assays. NAT was highly correlated with amino acids present in PN solutions, such as arginine, leucine, methionine, phenylalanine, and valine. In our sample cohort, we determined an NAT cutoff could aid the identification of misannotated neonates administered PN. We also report the Amadori rearrangement product valine–hexose (Val-Hex) was quantifiable in neonates administered PN, which we suspect forms in the PN solution and/or IV lines. Here, we present the first known use of NAT as a biomarker of PN administration, which is currently being piloted by two U.S. NBS laboratories. NAT and Val-Hex can aid the identification of misannotated DBSs from neonates administered PN, thus decreasing false positive rates.

25 June 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
SISamantha L Isenberg
Samantha L Isenberg
CPC. Austin Pickens
C. Austin Pickens
RLRachel Lee
Rachel Lee
CCCarla Cuthbert
Carla Cuthbert
Konstantinos PetritisKonstantinos Petritis
Konstantinos Petritis
Background/Objectives: Mass spectrometry-based newborn screening for small-molecule biomarkers typically employs a rapid first-tier screen that omits chromatographic separations before mass spectrometric analysis, followed, only for a subset of samples and disorders, by a longer, more specific second-tier assay that includes liquid chromatographic separation prior to mass spectrometry. The second-tier screen is used when the primary biomarker lacks sufficient specificity and may result in higher false-positive rates. The throughput and specificity of first-tier newborn screening assays have been relatively stagnant over the past two decades despite significant improvements in mass spectrometry instrumentation. With the continuous expansion of disorders added to the Recommended Uniform Screening Panel in the United States, newborn screening laboratories have a need for higher-throughput assays and improved specificity. Methods: We developed and evaluated two first-tier tandem mass spectrometry approaches using a modern dual-needle, dual-loop LC-MS/MS platform: (1) a 30-s flow injection analysis tandem mass spectrometry (FIA-MS/MS) assay and (2) a rapid first-tier liquid chromatography tandem mass spectrometry (LC-MS/MS) assay using a hydrophilic interaction chromatography (HILIC) guard column (1TH). Analytical performance was assessed using dried blood spot quality control and linearity materials, including evaluations of recovery, precision, linearity, and matrix effects. Results: The 30-s FIA-MS/MS assay quadrupled the throughput of current 2-min FIA-MS/MS assays used routinely in newborn screening laboratories. The throughput improvement was achievable due to increased scan speeds of the mass spectrometer as well as the dual needle/loop design of the autosampler. In addition, these instrumentation improvements made it possible to employ liquid chromatographic separations prior to MS/MS analysis without sacrificing the approximately 2-min sample-to-sample throughput of conventional FIA-MS/MS workflows. The 1TH LC-MS/MS method separated critical isobaric and isomeric biomarkers, reduced matrix effects, improved specificity and quantification accuracy, and demonstrated acceptable recovery, precision, and linearity for newborn screening applications. Conclusions: Recent advances in LC-MS/MS instrumentation can be leveraged to either substantially increase first-tier newborn screening throughput or improve analytical specificity while maintaining current workflow timelines. First-tier LC-MS/MS using a HILIC guard column provides improved specificity that can reduce the need for second-tier testing, thereby improving overall throughput and turnaround time of the newborn screening workflow. These approaches provide flexible solutions for newborn screening laboratories seeking to accommodate expanding screening panels without compromising analytical quality or efficiency.